In this study, we used DD3 promoter specificity to construct oncolytic adenovirus armed with SPAG9 shRNA to specially knockdown SPAG9 in PCa cells and examined whether constructed DD3-ZD55-SPAG9 improved the efficacy of DTX for PCa treatment in vivo and in vitro. This evidence concerns the gene SPAG9 and posterior cortical atrophy.